Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.47 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PTGFR | P43088 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | PTPRA | P18433 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6569465 | 0.98 | ALDH1A1 (0.49) | ALDH1A1CYP1A2TSHRGABBR2GABBR1 | |
| SCHEMBL12408231 | 0.90 | CYP1A2 (0.53) | ALDH1A1CYP1A2TSHRGABBR2GABBR1 | |
| SCHEMBL21632111 | 0.90 | GABBR2 (0.59) | ALDH1A1CYP1A2TSHRGABBR2GABBR1 | |
| SCHEMBL25152374 | 0.87 | ALDH1A1 (0.47) | ALDH1A1CYP1A2TSHRGABBR2GABBR1 | |
| SCHEMBL14421944 | 0.85 | CYP1A2 (0.46) | ALDH1A1CYP1A2TSHRGABBR2GABBR1 | |
| SCHEMBL25152820 | 0.84 | ALDH1A1 (0.44) | ALDH1A1CYP1A2TSHRGABBR2GABBR1 | |
| SCHEMBL11570903 | 0.84 | SMN1; SMN2 (0.46) | ALDH1A1CYP1A2TSHRLMNAPTPRA | |
| SCHEMBL25152454 | 0.84 | ALDH1A1 (0.44) | ALDH1A1CYP1A2TSHRGABBR2GABBR1 | |
| SCHEMBL4454418 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CYP1A2TSHRSLC6A2SLC6A4 | |
| SCHEMBL4454414 | 0.83 | ALDH1A1 (0.49) | ALDH1A1CYP1A2TSHRSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296726-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-29 | — | — | US | disclosed |
| US-20150051196-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-02-19 | — | — | US | disclosed |
| US-8895584-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-25 | — | — | US | disclosed |
| US-20140243382-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-28 | — | — | US | disclosed |
| US-8759347-B2 | Inhibitors of C-FMS kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-24 | — | — | US | disclosed |
| US-20130281475-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-24 | — | — | US | disclosed |
| US-8481564-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-07-09 | — | — | US | disclosed |
| US-20110195960-A1 | INHIBITORS OF C-FMS KINASE | ILLIG CARL R | 2011-08-11 | — | — | US | disclosed |
| EP-2021335-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-7414050-B2 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-7414050-B2 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| WO-2007124316-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| EP-0892790-B1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LAB (IT) | 2004-04-14 | — | — | EP | disclosed |
| US-5985885-A | USEFUL IN THE TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, PROSTATE HYPERTROPHY, VARIOUS URINARY TRACT DISORDERS AND PATHOLOGICAL SYMPTOMS CAUSED BY HYPERACTIVITY OR DISFUNCTIONING OF THE NORADRENERGIC NEURAL SYSTEM | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1999-11-16 | — | — | US | disclosed |
| EP-0892790-A1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997037979-A1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1997-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281475-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | ALDH1A1 4702/4885CYP1A2 3278/4885TSHR 1277/4885 |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, PNCK | ALDH1A1 3686/4885CYP1A2 2365/4885TSHR 1009/4885 |
| US-20150051196-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | ALDH1A1 4702/4885CYP1A2 3278/4885TSHR 1277/4885 |
| US-20140243382-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | ALDH1A1 4702/4885CYP1A2 3278/4885TSHR 1277/4885 |
| US-20110195960-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | ALDH1A1 4702/4885CYP1A2 3278/4885TSHR 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.